In collaboration with the New York Times, ProPublica authored a multi-part series on the falling cost of generic drugs and insurance. One article sought to answer what politicians and many consumers have been asking lately: If generics are cheaper, why are some insurance plans requiring consumers to use the more expensive brand name versions? ProPublica spoke to a California pediatrician who said he began receiving memos from pharmacies telling him that he had to prescribe name brand versions of attention deficit drugs such as Adderall XR.
ProPublica has revealed that deals with insurance companies and pharmacy benefit managers (companies such as CVS Caremark who manage drugs plans for insurance companies) are receiving kickbacks and deals, while leaving consumers footing the bill for higher out of pocket costs.
Adderall XR and Insurance Companies: Back Room Negotiations